words lines 0 60 0 20 top 50% bottom top 1 0 0 .22 back 1 0 .001 1 .1 1.5 none top bottom center center true 1 none top top center top true 0 200 .001 none
top bottom top center true 1 none top bottom bottom bottom true 1 none

Pipeline

Pipeline for continuous benefit to patients.

We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes first-in-class therapies aimed at providing new solutions and  support where no options currently exist, with a goal to help lift the burden for patients.

Anamorelin

ANAMORELIN is a novel once-daily, orally active ghrelin receptor agonist indicated for the treatment of cancer cachexia in patients suffering from malignant tumors of non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer or colorectal cancer. Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight (especially decreased muscle mass) and anorexia associated with cancer. It has been well documented that cancer cachexia causes a significant impact on patients’ quality of life (QOL) and prognosis.

Pre-clinical

Phase 1

Phase 2

Phase 3

Regulatory

%
Cancer Anorexia-Cachexia in NSCLC patients